Eli Lilly Q2 FY26 EPS rises 26% to $7.94; revenue increases 48% to $23 billion - LLY News | RalliesEli Lilly Q2 FY26 EPS rises 26% to $7.94; revenue increases 48% to $23 billion
L
LLY• Updated 2026 guidance
- Raised 2026 revenue guidance to USD 85-87 billion; updated non-GAAP EPS outlook to USD 35.5-36.5.
Second-quarter results
- Eli Lilly Q2 2026 revenue rose 48% to USD 23 billion, while GAAP EPS climbed 26% to USD 7.94.
- GAAP net income increased 25% to USD 7.1 billion, with results including USD 3.03 per share of acquired IPR&D charges.
- Non-GAAP EPS increased 33% to USD 8.38, despite USD 3.03 per share of acquired IPR&D charges.
Management commentary and pipeline update
- CEO David Ricks cited momentum, new manufacturing capacity coming online, pipeline additions, and plans to file retatrutide obesity BLA in Q1 2027.
•
